Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrEPared to Choose
PACTR202302499607694Phase 4Not yet recruiting
- Sponsor
- Desmond Tutu Health Foundation
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cabotegravir, dapivirine and emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Desmond Tutu Health Foundation. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
cabotegravirdapivirineemtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202302499607694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202302499607694.